Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Gossamer Bio (GOSS) over the last 7 years, with Dec 2024 value amounting to -$10.7 million.

  • Gossamer Bio's Change in Accured Expenses rose 161.07% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 148.25%. This contributed to the annual value of -$10.7 million for FY2024, which is 36.59% down from last year.
  • Gossamer Bio's Change in Accured Expenses amounted to -$10.7 million in FY2024, which was down 36.59% from -$7.8 million recorded in FY2023.
  • Gossamer Bio's Change in Accured Expenses' 5-year high stood at $5.8 million during FY2021, with a 5-year trough of -$10.7 million in FY2024.
  • In the last 3 years, Gossamer Bio's Change in Accured Expenses had a median value of -$7.8 million in 2023 and averaged -$6.7 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 165.41% in 2021, then plummeted by 373.00% in 2023.
  • Yearly analysis of 5 years shows Gossamer Bio's Change in Accured Expenses stood at -$8.8 million in 2020, then surged by 165.41% to $5.8 million in 2021, then slumped by 128.73% to -$1.7 million in 2022, then tumbled by 373.00% to -$7.8 million in 2023, then crashed by 36.59% to -$10.7 million in 2024.